Skip to Content

Posts tagged with "The Dark Side"

  • Drug Prices

    The Case of Marathon Pharmaceuticals

    So since drug pricing and FDA regulations are so much in the news, it would seem like the perfect time for a small company to game the system for big profits, right? That’s apparently what Marathon Pharmaceuticals believes. They just got approval for deflazacort, a steroid, as a treatment for Duchenne Muscular Dystrophy. Duchenne is… Read More
  • Business and Markets

    Not Quite What Friends Are For

    Folks who do industrial drug research know that they’re around proprietary information, and they generally know to keep quiet about it. That can be a bit of an odd feeling at first – I can remember getting together with some friends from school not long after I’d taken my first pharma job (they had also… Read More
  • The Dark Side

    The Predatory Publishers List Goes Dark

    I’ve been meaning to write about the sudden demise of Beall’s List of Predatory Publishers. I’ve referred to it several times over the years in posts about the lower (much lower) end of the scientific publishing world, and used it many times as a resource. To recap, while there are many reputable open-access publishers in… Read More
  • Cancer

    Be Sure The Funds Are Deposited

    I’ve written before here about the many people who are convinced that most (or all) diseases have to do with the body’s pH – most often, you hear that your body has to be alkaline, and that cancer and other diseases are associated with acidity. To save time, I will stipulate that this is bullshit. Read More
  • The Dark Side

    A Field Guide to Authorship Fraud

    Here’s a good overview at Nautilus of the various sorts of authorship fraud that takes place with scientific publications. The authors, Adam Marcus of Gastroenterology & Endoscopy News and Ivan Oransky of Retraction Watch, are focusing especially on the schemes that invent authors, co-authors, reviewers and so on, with many useful exampl… Read More
  • The Dark Side

    Unbowed at Theranos

    If you haven’t read this story on the person who appears to be the main Theranos whistleblower, do so immediately. Tyler Shultz is the grandson of George Shultz, who was one of the big names on the company’s board, and he started out enthusiastically. But as time went on, he realized that things were not… Read More
  • Clinical Trials

    Wholesale Clinical Data Fabrication

    Here’s a disturbing analysis of a long series of clinical trials conducted by Yoshihiro Sato and co-workers in Japan. As described in this article at Stat, Sato’s research (focusing on drug effects on hip fracture)  has been coming under question for some time now. He published results on 33 (!) clinical trials between 1997 and… Read More
  • The Dark Side

    Dupeless Needication

    Here are two papers have been going around on Twitter for a few days now. The first one is from a Hindawi title, “The Scientific World Journal”, from a group at the University of Malaya. And the second is from the same team (several overlapping co-authors), published a year or so later in Scientific Reports. Neither… Read More
  • Business and Markets

    A Biotech Center In. . .Northern Vermont?

    Have a look at this article from Bloomberg Businessweek, which is mostly about the abuse of a visa program (EB-5) meant to encourage investment in out-of-the-way or economically depressed areas of the US. That’s not necessarily a bad idea, but it seems to have been an invitation to a lot of abuse over the years… Read More
  • The Dark Side

    Pfizer Fires For Fakery

    Today’s second “bad behavior” story comes courtesy of Retraction Watch and Leonard Schneider’s For Better Science. Schneider has been tracking some problems with papers from Min-Jean Yin, who was working at Pfizer’s La Jolla site. Five papers that came out of her work there are now being retracted – duplicate im… Read More